TriMaximize
Research type
Research Study
Full title
A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extrafine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes
IRAS ID
294788
Contact name
Richard RUSSELL
Contact email
Sponsor organisation
Chiesi Ltd
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
This non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow MS (medium strength) or Trimbow HS (high strength) as per the marketing authorisation.
Asthma patients often need to use multiple inhalers as part of their therapy, which require different inhalation techniques. It has been shown that the use of several inhalers of different mode of action, design and dosage requirements may have a detrimental effect on patient adherence and subsequent treatment outcomes.
In this prospective, non-interventional trial, we aim to evaluate aspects of adherence to Trimbow® (beclometasone/formoterol/glycopyrronium), a single-inhaler triple therapy (SITT)as a maintenance treatment of asthma, to gather knowledge from routine care on whether appropriate step-up to SITT leads to greater adherence and better health outcomes.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
21/SC/0106
Date of REC Opinion
15 Apr 2021
REC opinion
Further Information Favourable Opinion